Otros idiomas Kineta, Inc.

Acciones

KA

US49461C1027

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:01 20/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,481 ^USD	+6,42 %		-7,50 %	-86,75 %

08/04	Kineta, Inc. informa en la AACR 2024 de los datos iniciales de respuesta clínica de su ensayo clínico de fase 1/2 Vista-101 en curso	CI
12/03	Kineta, Inc. Anuncia una actualización de su ensayo clínico en curso Vista-101 de fase 1/2 que evalúa Kva12123	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities	15/05
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial	08/04
Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial	08/04
Earnings Flash (KA) KINETA Posts 2023 Revenue $5.4M	21/03
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update	21/03
KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported	12/03
Kineta, Inc. Announces an Update on Its Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating Kva12123	12/03
Top Midday Decliners	29/02
Kineta Announces Restructuring and Exploration of Strategic Alternatives	29/02
Kineta, Inc. Terminates Employment of Pauline Kenny as General Counsel and Secretary	29/02
Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO	29/02
Kineta, Inc. Announces Restructuring and Workforce Reduction	29/02
Kineta Announces Exploration of Strategic Alternatives	29/02
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium	22/02
Kineta to Present at Upcoming Investor Conferences	14/02
Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series	07/02
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors	17/01
Kineta, Inc. Announces Update on Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Tumor Activity	17/01
Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event	04/01
Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer	13/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Kineta, Inc.

Acciones

KA

US49461C1027

Otros idiomas

Filtros